Impact of food intake on the pharmacokinetics of first-line antituberculosis drugs in Taiwanese tuberculosis patients  by Lin, Hsien-Chun et al.
Journal of the Formosan Medical Association (2014) 113, 291e297Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.jfma-onl ine.comORIGINAL ARTICLEImpact of food intake on the
pharmacokinetics of first-line
antituberculosis drugs in Taiwanese
tuberculosis patients
Hsien-Chun Lin a, Ming-Chih Yu a,b, Hsing-Jin Liu c,
Kuan-Jen Bai a,b,*a Division of Chest Medicine, Department of Internal Medicine, Wan Fang Hospital,
Taipei Medical University, Taipei, Taiwan
b School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan
c Division of Hematology and Oncology, Department of Internal Medicine, Wan Fang Hospital,
Taipei Medical University, Taipei, TaiwanReceived 22 July 2013; received in revised form 18 January 2014; accepted 26 January 2014KEYWORDS
first-line
antituberculosis
drugs;
food;
pharmacokineticsConflicts of interest: The authors h
* Corresponding author. Division of
Number 111, Section 3, Hsing-Long Ro
E-mail address: kjbai@wanfang.go
0929-6646/$ - see front matter Copyr
http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Under the directly observed treatment, short course (DOTS) program,
antituberculosis (anti-TB) medications were possibly taken at random time, regardless of
whether it was prior to or after meals. This study was to evaluate the impact of food intake
on pharmacokinetic profiles of first-line TB drugs in Taiwanese TB patients, as well as the rela-
tionship between drug levels and pharmacogenetics.
Methods: This open-label, randomized, cross-over study included newly diagnosed Taiwanese
TB patients treated between January 2010 and February 2011 at Taipei Medical University-Wan
Fang Hospital. Rifater [a fixed-dose combination formulation of isoniazid (INH), rifampicin
(RIF), and pyrazinamide (PZA)] and ethambutol (EMB) were given according to national TB
guidelines. Blood samples were collected prior to and 1 hour, 2 hours, 4 hours, 6 hours, and
10 hours after dosing under fasting or postprandial conditions. Pharmacokinetic parameters
of the maximum serum concentration (Cmax), time to Cmax, and area under the serum con-
centrationetime curve from the beginning to the 10th hour (AUC0e10) were calculated.
Results: Sixteen TB patients were included and received anti-TB treatment under the DOTS
program after discharge. The overall effects showed that food intake reduced the mean Cmax
(INH: 40.6%, RIF: 40.2%, EMB 34.4%, PZA: 24.4%) and AUC0e10 (INH: 21.3%, RIF: 26.4%, EMB:
12.2%, PZA: 12.0%). Meanwhile, food increased the time to Cmax (INH: 78.1%, RIF: 151.3%,
EMB: 41.4%, PZA: 148.9%).ave no conflicts of interest relevant to this article.
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292 H.-C. Lin et al.Conclusion: Significantly lower serum drug concentrations were observed under postprandial
conditions than fasting conditions for INH, RIF, and PZA. The impact of taking random anti-
TB drugs under the DOTS program instead of taking drugs regularly prior to meals requires
further study.
Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Pulmonary tuberculosis (TB) is a serious public health
problem worldwide. TB control depends critically on the
effective treatment of these patients.1 Directly observed
treatment, short course (DOTS) can result in improved
treatment completion2 and reduced drug resistance and
relapse rates.3 This program has been implemented in
Taiwan since 2006. Under the DOTS program, each anti-TB
medication dose is completed via good interaction and
cooperation between observers and TB patients. However,
the exact timing of drug administration may vary according
to the individual schedules of patients and observers. Pa-
tients often take anti-TB medications at random times,
possibly after meals. Reduced bioavailability of first-line
anti-TB drugs when dosing after meals has been reported
in numerous controlled trials.4 Most of these studies were
conducted in healthy4e12 and non-Asian individuals,13,14
and the impact of administration time differences on
treatment outcomes were also not explored in these
studies. Therefore, we designed this study to evaluate the
effects of food intake on the pharmacokinetics of first-line
anti-TB drugs in Taiwanese TB patients. Treatment
outcome was also explored in these patients under the
DOTS program.
Genetic polymorphisms for metabolization of isoniazid
(INH) were also examined. INH is primarily metabolized by
N-acetyltransferase 2 (NAT2),15 thus the genetic poly-
morphism related to its pharmacokinetics was studied.Pre-study potential eligible patients 
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Figure 1 Study design and protocol. In treatment A, study
agents (Rifater and ethambutol) were given approximately 45
minutes prior to breakfast. In treatment B, study agents
(Rifater and ethambutol) were given approximately 45 minutes
after breakfast.Patients and methods
Study participants
This prospective study was performed at Taipei Medical
University-Wan Fang Hospital, a 750-bed tertiary-care and
TB referral center in northern Taiwan. The present study
was approved by the institutional review board and all
participants provided informed consent. The inclusion
criteria were: age > 20 years; Karnofsky score > 50; clinical
and radiographic signs and symptoms consistent with pul-
monary TB as determined by the investigator; documented
positive microbiology diagnosis results indicating pulmo-
nary TB; receiving anti-TB drug treatment with Rifater [a
fixed-dose combination formulation of INH, rifampicin
(RIF), and pyrazinamide (PZA)] and ethambutol (EMB); and
willing to be hospitalized for at least 6 days from the first
dose of anti-TB drugs. Exclusion criteria were: previous
treatment for multi-drug resistant TB; extended-drug
resistant TB, or likely to require surgical procedure for
management of TB; alcohol or drug abuse that would
interfere with the ability to meet the study requirements;concomitant disorders or conditions for which EMB, INH,
RIF, or PZA are contraindicated; unable to meet selected
safety criteria obtained at screening laboratory parame-
ters; women who were pregnant or breastfeeding during
the treatment period; and participants with a known al-
lergy to the study drugs. All participants were able to un-
derstand and comply with the protocol requirements and
follow the instructions and protocol-stated restrictions.
Study design
Sixteen patients were included and separated into two
study arms in an open-label, randomized, two-way cross-
over method (Fig. 1). Demographic data, past history, and
basic laboratory data were recorded. Each patient received
an anti-TB treatment regimen determined by the in-
vestigator’s judgment and according to the Taiwan Guide-
lines on TB Diagnosis and Treatment.16 All patients took
four first-line anti-TB drugs, which had been administered
for at least 4 days to reach steady state concentrations
prior to comparing the pharmacokinetics between fed and
fasted states in two study periods. Dietary components
included 52e58% carbohydrate, 16e19% protein, and
26e30% fat. Side effects of the four first-line anti-TB drugs
were also monitored and recorded.
Blood samples were collected 1 hour predose and 1 hour,
2 hours, 4 hours, 6 hours, and 10 hours postdose to obtain
pharmacokinetic profiles (Fig. 2), including maximum
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(Tmax), and the area under concentrationetime curve from
the beginning to the 10th hour (AUC0e10). Serum drug con-
centrations were measured using high-performance liquid
chromatography coupled with tandem mass spectroscopy
(LC-MS/MS; Fig. 3).
Pharmacogenomics analysis was also conducted for INH.
Genetic polymorphisms of NAT2 were examined. The rela-
tionship between INH pharmacokinetics and NAT2 genetic
polymorphisms was investigated.
Study agents
Each Rifater tablet contained 120 mg RIF, 80 mg INH, and
250 mg PZA. Doses were three tablets for patients <40 kg,
four tablets for patients >40 kg and <50 kg, and five tablets
for patients >50 kg once daily. The EMB dose was
15e25 mg/kg once daily. All study medications were sup-
plied by the Taipei Medical University-Wan Fang Hospital
pharmacy.
Statistical analysis
The paired t test was used for comparison of the pharma-
cokinetic profile differences between the two dietary sta-
tuses. Analysis of variance (ANOVA) was used to assess for
pharmacokinetic profile differences between the three
NAT2 genotype groups. A p value < 0.05 was considered
statistically significant.Figure 2 Time sequence of serum concentrations of aResults
The demographic data of the 16 included patients are
shown in Table 1. Nine patients had diabetes mellitus and
three were hepatitis B virus carriers. The basic liver and
renal function of all patients was normal.
Table 2 shows the results of the pharmacokinetic
studies. The overall effects showed that food intake
reduced the mean Cmax (INH: 40.6%, RIF: 40.2%, EMB
34.4%, PZA: 24.4%) and AUC0e10 (INH: 21.3%, RIF: 26.4%,
EMB: 12.2%, PZA: 12.0%). Meanwhile, food increased the
Tmax (INH: 78.1%, RIF: 151.3%, EMB: 41.4%, PZA: 148.9%).
The NAT2 genotype distribution of the 16 TB patients is
shown in Table 3. These data show that the NAT2 genotypes
do not significantly affect Cmax, but have a significant ef-
fect on AUC0e10 (p Z 0.001).
All patients completed the study and only one patient
experienced thesideeffect ofnauseaduring thestudyperiod.
All patients were treated under the DOTS program after
discharge. Of these 16 patients, 14 (87.5%) had successful
treatment and two (13.5%) died from non-TB diseases (1 from
cardiovascular disease and 1 from lung cancer). The treat-
ment success rate was higher than that of TB patients under
the DOTS program in Taiwan during the same period.17Discussion
Administration of anti-TB drug such as RIF is recommended
prior to meals by the World Health Organization. Somentituberculosis drugs taken prior to and after meals.
Figure 3 Maximum serum concentration (Cmax) and area under the concentration-time curve from the beginning to the 10th hour
(AUC0e10) values of isoniazid in patients with different NAT2 genotypes.
Table 2 Pharmacokinetic profiles of four first-line anti-
294 H.-C. Lin et al.reports found lower serum concentrations of anti-TB med-
ications taken postprandially, primarily in healthy volun-
teers or non-Asian TB patients.4e14 In the present study, we
also observed significantly lower serum drug levels (Cmax
and AUC0e10) of INH, RIF, and PZA under postprandial con-
ditions in Taiwanese TB patients. Thus, to achieve
adequate serum drug concentrations, clinicians should be
aware of the timing of anti-TB drug administration in these
patients.
Studies of low Cmax values of anti-TB drugs were con-
ducted worldwide beginning in the 1950s and validated at
the National Jewish Medical and Research Center (NJMRC)
in Denver, Colorado, USA in the 1990s.6,10,12,18e21 Low Cmax
values were defined as INH < 3 mg/mL (300-mg dose) or
<4 mg/mL (400-mg dose), RIF < 8 mg/mL, PZA < 35 mg/mL,Table 1 Demographic and baseline laboratory data of 16
study participants.
Characteristics and
baseline data
Mean  standard
deviation or n (%)
Age, (y) 63.06  14.37
Sex
Male 11 (69)
Female 5 (31)
Body mass index, kg/m2 20.64  4.19
Smoking 8 (50)
Comorbidity
Diabetes mellitus 9 (56)
Hepatitis B virus carrier 3 (19)
Cardiovascular diseases 5 (31)
Baseline serum tests
GOT, mg/dL 23.38  5.92
GPT, mg/dL 18.0  6.12
Cr, mg/dL 0.77  0.25
Ccr, mL/(min$1.73 m2) 78.64  30.65
Glucose, random, mg/dL 196.38  119.26
ALP, mg/dL 80.38  28.08
Total bilirubin, mg/dL 0.52  0.17
Uric acid, mg/dL 6.23  2.14
ALP Z alkaline phosphate; Ccr Z estimated creatinine clear-
ance; Cr Z creatinine; GOT Z glutamic-oxaloacetic trans-
aminase; GPT Z glutamic-pyruvic transaminase.and EMB < 2 mg/mL; very low Cmax values were defined as
INH < 2 mg/mL (300-mg dose) or <3 mg/mL (400-mg dose),
RIF < 4 mg/mL, PZA < 20 mg/mL, and EMB < 1 mg/mL. Ac-
cording to these reference ranges, some studies have
explored the rate of low serum drug concentrations in TB
patients. One study reported the prevalence of a low 2-
hour serum concentration of at least one anti-TB drug to
be 46.4% in South Korea.22 Another study found that low
serum Cmax values (<2 mg/mL) of EMB were present in 29%
of adult and 50% of child TB patients.23 In an Australian
study, 46% of patients had a 2-hour RIF concentration below
the normal range and 48% of patients had a 2-hour INHtuberculosis (TB) drugs.
Anti-TB drugs Drugs before
a meal
Drugs after
a meal
p
INH
Cmax, mg/mL 9.21  2.98 5.47  2.24 <0.001
AUC0e10,
mg‧(h/mL)
24.38  13.48 19.19  10.07 0.003
Tmax, h 1.01  0.07 1.81  0.75 <0.001
RIF
Cmax, mg/mL 15.92  8.98 9.52  6.93 <0.001
AUC0-10,
mg‧(h/mL)
75.13  63.53 55.31  57.14 <0.001
Tmax, h 1.39  0.80 3.50  0.89 <0.001
PZA
Cmax, mg/mL 41.75  11.78 31.57  10.84 <0.001
AUC0e10,
mg‧(h/mL)
258.08  77.04 227.11  77.60 <0.001
Tmax, h 1.08  0.26 2.69  1.08 <0.001
EMB
Cmax, mg/mL 3.87  1.53 2.54  0.92 0.001
AUC0e10,
mg‧(h/mL)
15.48  6.36 13.60  5.32 0.051
Tmax, h 1.81  0.75 2.56  1.21 0.061
Data are mean  standard deviation.
AUC0e10 Z area under the concentration-time curve from the
beginning to the 10th hour; Cmax Z maximum serum concen-
tration; EMB Z ethambutol; INH Z isoniazid;
PZAZ pyrazinamide; RIFZ rifampicin; TmaxZ time of Cmax.
Table 3 Pharmacokinetic parameters of INH in different NAT2 genotypes.
Rapid acetylation Intermediate acetylation Slow acetylation p
Distribution of NAT2 genotype,
n Z 16 (%)
n Z 6 (37)
*4/*4d6
n Z 7 (44)
*4/*6d4
*4/*7d3
n Z 3 (19)
*5/*6d1
*6/*6d1
*7/*7d1
Mean Cmax, mg/mL 7.71 9.42 11.71 0.162
Mean AUC0e10, mg‧(h/mL) 15.61 23.15 44.81 0.001
AUC0e10 Z area under the concentration-time curve from the beginning to the 10
th hour; Cmax Z maximum serum concentration;
INH Z isoniazid; NAT2 Z N-acetyltransferase 2 gene.
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ment outcomes were not mentioned in these studies.
Other studies investigated the relationship between
drug concentrations and treatment outcomes. A low INH
concentration was reported to be associated with increased
treatment failure/relapse in a once-weekly INH/rifa-
pentine regimen compared to a twice-weekly INH/RIF
regimen in human immunodeficiency virus (HIV)-negative
patients.25 Low PZA Cmax was associated with a higher risk
of poor treatment outcome, but pharmacokinetic parame-
ters (Cmax and AUC0e6h) of INH, RIF, and EMB were not
associated with treatment outcome in predominantly HIV-
infected TB patients.26 Another study found no associa-
tion between Cmax of RIF and slow culture conversion in
Hong Kong.27 The results of these studies varied and were
inconclusive. In the present study, the low serum Cmax
rates for each drug were 0% for INH, 12.5% for RIF, 31.6% for
PZA, and 12.5% for EMB when administered prior to meals
and 12.5% for INH, 68.8% for RIF, 62.5% for PZA, and 37.5%
for EMB when administered after meals according to the
NJMRC reference ranges. The treatment success rate was
87.5% in the present study when patients took drugs under
the DOTS program.
There are no precise targets for peak serum concentra-
tions relative to the minimal inhibitory concentration (MIC)
or time above MIC of anti-TB drugs derived from human
studies.20 However, there are reference ranges of expected
serum drug concentrations under usual adult doses in
healthy volunteers, but not the minimally effective con-
centration.20,21 The reference ranges are 3e6 mg/mL for
INH (300 mg 4 times daily), 8e24 mg/mL for RIF (600 mg 4
times daily), 20e25 mg/mL for PZA (25 mg/kg 4 times daily),
and 2e6 mg/mL for EMB (25 mg/kg 4 times daily).20 In vitro,
the MICs of anti-TB drugs in agar medium are 0.1e0.2 mg/
mL for INH, 0.125e0.5 mg/mL for RIF, and 1.9e7.5 mg/mL
for EMB,28 indicating that the MICs of INH and RIF in agar are
lower than the lower reference range limits. When MIC
tests are performed in broth, these values are even lower
(0.025e0.05 mg/mL for INH, 0.06e0.25 mg/mL for RIF, and
0.95e1.9 mg/mL for EMB) than those in agar.28 The broth-
determined MIC are likely to be much closer to the true
MIC values.
To improve TB treatment adherence, DOTS has been
recommended as the standard of care,29,30 which was
implemented in Taiwan in 2006. However, many patients
could not take anti-TB drugs prior to meals under the DOTS
program, thus possibly decreasing the drug serum concen-
trations. In the present study, the treatment success ratewas 87.5% under the DOTS program. Further study is war-
ranted regarding possibly decreased serum concentrations
of anti-TB drugs when taken after meals under the DOTS
program and treatment outcome. One possible explanation
is that serum drug concentrations were sufficient to kill
bacteria even with postprandial drug administration, as
these serum drug concentrations are much higher than the
MIC. Organ penetration of drugs should also be considered.
In a pharmacokinetic study of RIF, high drug concentrations
in the sputum and cavitary fluid of TB patients were
observed.31
The pharmacokinetics of anti-TB drugs and their me-
tabolites are associated with genetic polymorphisms of
drug-metabolizing enzymes such as NAT2, cytochrome P450
2E1, and glutathione S-transferase.15 In the present study,
when drugs were taken prior to meals, the mean Cmax
values of INH were slightly different between the three
NAT2 polymorphism groups (p Z 0.162) and the mean
AUC0e10 values of INH were significantly different between
these groups (p Z 0.001; Table 3). These results were
similar to those of previous pharmacokinetic studies of
INH.10,19 When taken after meals, the mean Cmax of INH
was 4.73 mg/mL in the rapid acetylator group, 5.89 mg/mL
in the intermediate acetylator group, and 5.95 mg/mL in
the slow acetylator group. Two patients had Cmax values of
INH lower than the low Cmax (<3 mg/mL) NJMRC reference
range: one Cmax of 2.20 mg/mL in a rapid acetylator and a
Cmax of 2.71 mg/mL in an intermediate acetylator, both of
which were above the MIC value determined in agar
(0.1e0.2 mg/mL) or broth (0.025e0.05 mg/mL). NAT2 poly-
morphisms are associated with anti-TB drug-induced liver
injuries.32 However, all of our patients had normal liver
function during the study period and the relationship be-
tween NAT2 polymorphisms and hepatitis could not be
explored in the present study.
Dietary components also affect serum drug concentra-
tions. A high-fat meal as recommended by the Food and
Drug Administration in the USA reduced the INH Cmax by
32e51% and AUC by 12e13% in two studies.8,10 In other
studies, a carbohydrate-based diet reduced the INH Cmax
and AUC to levels lower than those of high-fat meals.8,14
The Tmax of RIF was increased more by carbohydrate
than by lipid.14 In the present study, all patients ate food
with the same components, containing 52e58% carbohy-
drate, 16e19% protein, and 26e30% fat. Thus, the
different serum concentrations of anti-TB drugs among
these patients were not caused by different dietary
components.
296 H.-C. Lin et al.There was a substantial proportion of patients having
comorbidities: 56% with diabetes mellitus, 31% with car-
diovascular disease, and 19% with hepatitis B virus carrier.
Drug interactions should be considered in the pharmacoki-
netic study and all medication for these comorbidities were
reviewed. The effects of some drugs may be interfered by
INH and/or RIF, such as sulfonylurea, metformin, acarbose,
calcium channel blockers, angiotensin receptor blockers, b-
blockers, a-blockers, and clopidogrel. However, there is no
report of these medications’ effects on anti-TB drugs and
treatment outcomes in a literature review. It would be of
interest to carry out further studies to determine the
impact of food intake between TB patients with and
without comorbidity.
As the incidence of TB decreases over time, treatment
of latent TB infection (LTBI) is becoming important in
eliminating this disease. In Taiwan, LTBI therapy with 9
months of INH is recommended in close contacts younger
than 25 years, which is also covered by the DOTS program.33
The possible effects of food intake on treatment outcome
of LTBI should also be considered in a further study.
There were several limitations in the current study.
First, there was a small patient number to explore the ef-
fect of serum concentrations of anti-TB drugs on treatment
outcome under DOTS program, and we did not have records
of patient status prior to or after meals throughout the
entire treatment course. Second, HIV status was not
routinely checked, which could interfere with serum con-
centrations of anti-TB drugs,34 despite the low HIV preva-
lence in Taiwanese TB patients (0.8e2.5%).17 Third, serum
RIF concentrations under daily dosing will not reach a sta-
ble status even after 14 days of usage,31 whereas our study
was conducted only 4 days after beginning treatment. It is
possible that there are lower RIF serum concentrations
after long-term treatment than those reported in this
study. As for INH, PZA, and EMB, no pharmacologic data
revealed different drug levels between initial and long-
period usage in literature.
From a pharmacokinetic point of view, there were sig-
nificant differences between fasting and postprandial con-
ditions when taking anti-TB drugs. In the present study,
treatment outcomes were good under the DOTS program.
However, there was limited case number for evaluation of
treatment outcome in the present study. Thus, the impact
of random timing of anti-TB drug administration instead of
prior to meals with the DOTS program should be carefully
evaluated in TB patients in further larger study.References
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